RESEARCH ARTICLE

REVISED Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort [version 2; peer review: 1 approved, 2 approved with reservations]

Previously titled: 'Neurocognitive outcomes of HIV associated tuberculous meningitis'

Carson M Quinn ¹⁻³, John Kasibante ², Alice Namudde²,
Ananta S Bangdiwala ⁴, Mable Kabahubya², Noeline Nakasujja^{2,5,6},
Sarah Lofgren ⁷, Alison Elliott ^{8,9}, David R Boulware ⁷, David B Meya ²,
Fiona V Cresswell ^{2,8,10}

¹School of Medicine, University of California San Francisco Medical Center, San Francisco, CA, USA

²Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

³Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

⁴Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA

⁵Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda

⁶Department of Psychiatry, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda

⁷Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, 55455, USA

⁸Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK

⁹Medical Research Council/Uganda Virus Research-Institute Uganda Research Unit on AIDS, Entebbe, Uganda

¹⁰Division of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, UK

v2 First published: 12 Aug 2021, 6:208
<https://doi.org/10.12688/wellcomeopenres.16967.1>

Latest published: 03 Mar 2022, 6:208
<https://doi.org/10.12688/wellcomeopenres.16967.2>

Abstract

Background: The toll of tuberculous meningitis (TBM) in both mortality and disability is considerable, but advancements in rehabilitation have the potential to improve the functional abilities and the quality of survivors' lives. However, the typical phenotype of neurocognitive impairment in TBM survivors remains unstudied in HIV-predominant populations in sub-Saharan Africa.

Methods: We tested 36 survivors of TBM in Uganda with a comprehensive battery of neurocognitive assessments at 8 and 24 weeks after diagnosis, and compared results to a representative cohort of HIV-uninfected Ugandans.

Results: While participants had a broad range of impairments at eight weeks, there was marked improvement by 24 weeks, when a phenotype of impairment including deficits in motor functioning, verbal learning and memory, processing speed, and executive function emerged. These deficits were present despite good clinician-rated functional status. The majority (23/27, 85%) had evidence of moderate to severe depression at week 8, and at week 24 (18/24,

Open Peer Review

Approval Status

	1	2	3
version 2			
(revision)			
03 Mar 2022	view		view
version 1			
12 Aug 2021	view	view	
1. Deanna Saylor , Johns Hopkins University, Baltimore, USA			
University Teaching Hospital, Lusaka, Zambia			
University of Zambia, Lusaka, Zambia			
2. Reuben Robbins , New York State Psychiatric Institute, New York City, USA			

75%).

Conclusion: These findings highlight the need for more comprehensive neurocognitive assessment in the survivors of TBM, and further investment in and study of rehabilitation, including management of depression, to improve long-term outcomes in this population.

Keywords

Tuberculous Meningitis, HIV, neurocognitive, functional, psychiatric, depression

Columbia University, New York City, USA

3. **Pablo F. Belaunzarán-Zamudio** , National Institutes of Allergy and Infectious Diseases (Contractor), Mexico City, Mexico

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Fiona V Cresswell (fiona.cresswell@lshtm.ac.uk)

Author roles: **Quinn CM:** Conceptualization, Data Curation, Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kasibante J:** Conceptualization, Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Namudde A:** Data Curation, Investigation, Methodology, Writing – Review & Editing; **Bangdiwala AS:** Data Curation, Formal Analysis, Methodology, Validation, Writing – Review & Editing; **Kabahubya M:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Nakasujja N:** Data Curation, Investigation, Methodology, Supervision, Writing – Review & Editing; **Lofgren S:** Writing – Original Draft Preparation, Writing – Review & Editing; **Elliott A:** Funding Acquisition, Resources, Supervision, Writing – Review & Editing; **Boulware DR:** Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Review & Editing; **Meya DB:** Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Review & Editing; **Cresswell FV:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome (210772/Z/18/Z to FVC) and National Institute of Neurologic Diseases and Stroke and Fogarty International Center (R01NS086312); National Institute of Allergy and Infectious Diseases (R01AI145437). FVC and AE are honorary fellows of the Makerere University – Uganda Virus Research Institute Centre of Excellence for Infection and Immunity Research and Training (MUII-plus). MUII-plus is supported through the DELTAS Africa Initiative (Grant no. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no. 107743) and the UK Government.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Quinn CM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Quinn CM, Kasibante J, Namudde A *et al.* **Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort [version 2; peer review: 1 approved, 2 approved with reservations]** Wellcome Open Research 2022, 6:208 <https://doi.org/10.12688/wellcomeopenres.16967.2>

First published: 12 Aug 2021, 6:208 <https://doi.org/10.12688/wellcomeopenres.16967.1>

REVISED Amendments from Version 1

Adjustments were made to the text based on recommendations from reviewers. These include additional limitations of the study regarding language of assessment administration, practice effects, and the inability to draw conclusions on the impact of trial treatments and HIV status. Two new tables and associated text passages were added to provide data on the HIV-negative control group (Table 2), and to detail the neurocognitive testing results when severely impaired participants were included and excluded (Table 5). The title was modified to better reflect that the population in the study was primarily HIV-positive.

Any further responses from the reviewers can be found at the end of the article

Introduction

Tuberculous meningitis (TBM) continues to incur unacceptably high mortality, especially in people living with HIV, in whom it can exceed 50%^{1,2}. The persistence of neurologic sequelae in those who survive has been long-recognized, and can include major neurologic deficits such as hemiplegia and blindness, as well as more subtle cognitive changes such as memory or psychiatric problems^{3,4}. The various neurologic sequelae have been reported to affect a third to a half of survivors in some series^{1,2}. These long-term neurological complications are attributed to hydrocephalus⁵, decreased grey matter volume⁶, and stroke, which may occur in as many as 57% of patients^{7,8}.

The most commonly employed assessments for long-term morbidity in TBM are the modified Rankin Scale or Barthel Index, with recent meta-analyses reporting some physical disability in 32% of TBM survivors, using these tools¹. While the importance of severe disability is recognized, and often an endpoint in TBM clinical trials⁹, these broad measures can miss the more subtle neurocognitive changes in TBM patients that can still impact overall wellbeing and economic output¹⁰. Two Indian cohort studies used the Mini Mental Status Exam and found cognitive impairment in over half of survivors at six months and one year after TBM diagnosis^{11,12}. Comprehensive neuropsychological testing using the Wechsler Adult Intelligence Scale in 17 TBM patients in Taiwan showed impairment in multiple domains including working memory and verbal comprehension⁶. However, these studies in HIV-negative populations may not be representative of TB-HIV coinfection, as HIV, both independently and in conjunction with TB, contributes to neurocognitive impairment^{13,14}; yet, TBM in HIV-infected persons is less inflammatory¹⁵. Given recent findings of variability in reliability of cognitive assessments across different regional and cultural settings¹⁶, it is essential that neurocognitive assessments are modified and standardized to local norms, as has been successfully applied in past studies of neurocognitive outcomes after cryptococcal meningitis^{17,18}. Comprehensive neuropsychological testing has never been reported after TBM in a primarily HIV-positive population or in sub-Saharan Africa. Furthermore, despite evidence of increased risk of mental illness in childhood survivors

of TBM¹⁹, the burden of depression in adult survivors of TBM is unknown.

Given the prevalence of disability in TBM survivors, further understanding of rehabilitation options is necessary. In 2017, the World Health Organization (WHO) identified rehabilitation as an increasing unmet need to address disability in low and middle income countries, and called for strengthening of these systems²⁰. In Uganda, availability of physiotherapy remains limited, and is often restricted to those with higher socioeconomic status and education²¹. Neurorehabilitation has emerged as a specialized form of rehabilitation incorporating physiotherapy as well as occupational, speech, and psychiatric therapy, to target the potential for brain recovery in neurological diseases such as stroke and multiple sclerosis²². Groups in India and West Africa have investigated telemedicine strategies for the rehabilitation of survivors of stroke, TBM, and other neurologic illnesses to overcome implementation barriers that exist in resource-limited settings^{23,24}.

To better target neurorehabilitation resources, a clearer phenotype of the neurocognitive and functional impairment in TBM is necessary. In this nested prospective cohort study, we assessed detailed neurocognitive function, alongside depression and functional status, in Ugandan clinical trial participants who survived TB meningitis. To describe the cognitive deficits associated with TBM and their improvement over the first 6 months of recovery, tests were repeated at 8 and 24 weeks, and compared with a representative healthy control group.

Methods

Population and setting

Patients were enrolled in this prospective cohort from within the “*High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis*” (RIFT) study, a phase 2 open-label randomized trial (ISRCTN42218549)²⁵. Patients were enrolled in the parent trial between January 14 and December 17, 2019, at Kiruddu National Referral Hospital in Kampala, Uganda and Mbarara Regional Referral Hospital in Mbarara, Uganda, based on detection of TB in the cerebrospinal fluid (CSF) by Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, CA)²⁶, or presentation compatible with TBM (CSF:plasma glucose ratio <50% or CSF glucose <65 mg/dL), coupled with TBM treatment planned. Exclusion criteria and study drug administration details are provided in the published trial protocol²⁷. We recorded baseline clinical data, CSF results, and demographics at initial presentation. Adjunctive corticosteroids were administered to all patients and antiretroviral therapy (ART)-naïve individuals initiated ART after completion of the intensive phase of TB treatment (week 8), in accordance with Ugandan guidelines (tenofovir/lamivudine/dolutegravir as first-line). HIV-positive participants also received cotrimoxazole prophylaxis.

We enrolled participants into this sub-study assessing neurocognitive and functional outcomes from the Kampala site eight weeks after their enrollment in the parent trial.

We included those who survived the initial hospitalization and presented for their week eight post-randomization clinic follow-up visit. We excluded patients whose meningitis was later confirmed to be due to a non-TB etiology.

Procedures

At week 8 and 24 visits, patients' clinical status was recorded, as was their modified Rankin score and Karnofsky performance score, clinician-determined functional status measures. They were screened for depression using the patient health questionnaire (PHQ)-9 instrument, which ranges from 1 to 27 and has been validated in multiple countries in sub-Saharan Africa with a cutoff of 10 for moderate or severe depression^{28,29}. We used a secondary cutoff of 15 to account for possible overlap in physical symptoms with TBM illness. As part of the visit, participants received a standardized battery of neurocognitive tests in either English or Luganda performed by a trained study nurse. The battery of tests evaluates ten neuropsychological and motor domains, and has been validated in sub-Saharan African populations and performed in Uganda on survivors of cryptococcal disease^{17,30}. These tests have become the standard for use in Uganda as past studies have validated the Luganda translations³¹, and shown minimal difference in score based on English or Luganda administration³². The WHO-University of California-Los Angeles Auditory Verbal

Learning Test (WHO-UCLA AVLT) assesses verbal learning and memory³³, Digit Span Forward and Backward assesses attention and working memory³⁴, Semantic Verbal Fluency assesses language fluency³⁵, Timed Gait assesses gross motor function³⁶, Grooved Pegboard (average of both hands) assesses fine motor function³⁷, Finger Tapping (of the dominant hand) assesses motor speed³⁸, Symbol Digit Modality assesses processing speed and concentration³⁹, Color Trails 1 assesses processing speed and attention, and Color Trails 2 assesses executive function⁴⁰, (Table 1).

Statistical analyses

Raw scores on each test were standardized to duration of education (<7 years, 7 to 12 years, and >12 years) and age (greater or less than 30 years), matched to HIV-negative Ugandan controls (data collected as part of a prior neurocognitive study^{32,41} and summary statistics presented in Table 2) to create education- and age-adjusted Z-scores. To generate a global measure of neurocognitive function across all domains, a quantitative neurocognitive performance Z-score (QNPZ-8) was calculated as the mean of eight individual Z-scores: Symbol Digit, WHO-UCLA AVLT immediate and delayed recall, Verbal Fluency, Color trails 1 and 2, Finger Tapping, and Grooved Pegboard. We defined neurocognitive impairment as one standard deviation below the HIV-negative reference mean

Table 1. Neuropsychological test battery and neurocognitive domains evaluated.

Test	Test Description	Cognitive Domains
WHO-UCLA AVLT-Total*	Subjects are asked to recall a list of words. The test is similar to the Rey Auditory Verbal Learning test, however words have been selected to be recognizable to a variety of cultures	Verbal learning
WHO-UCLA AVLT-Delayed Recall*	Similar to WHO-UCLA AVLT, but subjects are asked to recall the same list of words in a delayed recall phase	Verbal memory
Digit Span Forward and Backward	Subjects are given a series of digits of increasing length and are asked to repeat them in forward or backward order	Attention, Working memory
Semantic Verbal Fluency	Subjects are given 60 seconds to produce as many words as possible within a specific category such as 'animals'	Language fluency (Verbal)
Symbol Digit Modality	Subjects are asked to match geometric figures to numbers as quickly as possible over 90 seconds using a visual reference.	Speed of information processing, Concentration
Color Trails 1	Subjects connect encircled numbers scattered on a page in sequence during a set amount of time. This test is similar to the Trail Making Test but has been formulated to minimize cultural bias by not using any letters or written instructions	Speed of information processing, Attention
Color Trails 2	Similar to The Color Trails 1 but each number is printed in two different colors, and subjects are asked to maintain the numerical sequence while alternating colors	Executive function
Timed Gait	The time for subjects to walk out and back 10 meters is recorded	Gross motor
Grooved Pegboard	Subjects are timed while placing pegs which each have a key along one side in holes in various orientations in a pegboard with either their dominant or non-dominant hand	Fine motor
Finger tapping	Subjects tap as rapidly as possible using the index finger on a specially adapted tapper for five 10-second trials	Motor speed

WHO-ULCA AVLT = World Health Organization-University of California-Los Angeles Auditory Verbal Learning test

(corresponding to a Z-score of -1) and severe impairment as two standard deviations (Z-score < -2). Participants were permitted to skip tests if they started but were unable to complete it due to visual difficulties, fatigue, or physical limitations. Skipped tests were assigned Z-scores equal to the mean of the TBM cohort minus two standard deviations. All analyses were run on [STATA](#) version 15 (StataCorp, College Station, TX).

Ethical considerations

Written informed consent was obtained from participants or their caregiver. The parent trial and this sub-study were approved by the Research Ethics Committees of LSHTM, UK,

Mulago Hospital, Uganda National Council of Science and Technology, and Uganda National Drug Authority. An independent data safety committee reviewed accruing data from the parent trial.

Results

Cohort

Of 56 patients enrolled in the parent trial at Kampala, 37 survived and remained at eight weeks follow-up to be considered for enrollment in this study ([Figure 1](#)). The 19 not considered for enrollment either did not survive to week 8 (n=14), were withdrawn from the parent trial during the initial hospitalization (n=3), or were unable to present to their week 8 visit and later died (n=2). We enrolled 36 patients into the neurocognitive study after excluding one who had an alternate etiology of meningitis. Of the 36, 28 were reassessed at week 24 (n=6 died, n=2 declined assessment at week 24).

Demographics and clinical data from the initial hospitalization are presented in [Table 3](#). The cohort was relatively young (median age 35). Overall, 42% (15/36) had less than 7 years of education, 39% (n=14) had seven to 12 years of education, and 19% (n=8) had more than 12 years of education. Compared to the HIV-negative control group ([Table 2](#)), there was a higher proportion with fewer years of education, but age and gender were similar. Overall, 94% (34/36) were HIV-positive, and 44% (16/36) had microbiological-confirmed TBM. Due to low numbers in each experimental treatment group (standard of

Table 2. Demographic data on HIV-negative control cohort (n=100).

Characteristics at Enrollment	
Age, years	31 (27-35)
Women	53 (53%)
Education <7 years	18 (18%)
7–12 years	60 (60%)
>12 years	22 (22%)

Values are medians with interquartile range (IQR) or N (%).

Figure 1. Enrollment in this nested sub-study from the parent randomized RIFT trial.

Table 3. Baseline results in persons with TBM.

Characteristics at Diagnosis	
Age, years	35 (29-37)
Women	18 (50%)
Education <7 years	15 (42%)
7-12 years	14 (39%)
>12 years	7 (19%)
HIV-positive	34 (94%)
Receiving ART (of HIV-positive)	12 (35%)
CD4 count, cells/ μ L	111 (43-272)
CD4 count <200 cells/ μ L	19 (61%)
Microbiologically-confirmed TBM	16 (44%)
Trial Arm: Standard of Care	15 (42%)
High dose oral rifampin	10 (28%)
High dose IV rifampin	11 (31%)
TBM severity: MRC grade	
1	4 (11%),
2	27 (75%),
3	5 (14%)
Glasgow Coma Scale score	14 (12-14)
CSF White Blood Cell Count, cells/ μ L	35 (<5-125)
CSF Protein, mg/dL	128 (94-177)
CSF Glucose, mg/dL	41 (21-68)
Serum Sodium, mEq/L	130 (126-136)

Values are medians with interquartile range (IQR) or N (%).

ART: antiretroviral therapy, TBM: Tuberculous meningitis, MRC: medical research council grade, CSF: cerebrospinal fluid.

care n=15, high dose oral rifampin n=10, high dose intravenous rifampin n=11), neurocognitive data is described for the cohort as a whole rather than by randomized treatment group from the parent trial; data from the parent trial suggests no significant difference in function outcomes or mortality between the treatment groups²⁵.

Week 8 neurocognitive assessment

At eight weeks, 11 patients had at least moderate disability with a modified Rankin Scale score greater than or equal to 3 (median cohort score = 2, IQR 1-3), and 75% (27/36) of patients had Karnofsky scores <80, indicating inability to carry on normal activity (Table 4).

At week 8, 86% (31/36) of patients had impaired cognitive function (QNPZ-8 lower than -1), and 53% (19/36) had severe impairment (QNPZ-8 lower than -2). The mean QNPZ-8 score was -2.51 (standard deviation ($\pm$ SD) $\pm$ 1.43) representing 2.51 standard deviations (i.e. Z-score) below the control group mean for HIV-negative Ugandans, adjusted for age and education. At eight weeks, impairment was nonspecific as all

Table 4. Week 8 and 24 neurocognitive and functional outcomes in persons with tuberculosis meningitis.

	Week 8	Week 24
modified Rankin Scale > 2	11 (31%)	3 (10%)
Karnofsky Functional Status Score < 80	27 (75%)	6 (21%)
PHQ-9 Depression Score $\geq$ 10	23 (85%)	18 (75%)
PHQ-9 Depression Score $\geq$ 15	19 (70%)	14 (58%)
QNPZ-8 Neurocognitive <-1 Z-score	31 (86%)	17 (61%)
QNPZ-8 Neurocognitive <-2 Z-score	19 (53%)	7 (25%)

Abbreviations: PHQ-9: patient health questionnaire 9

component assessments of the QNPZ-8 demonstrated cognitive impairment (Z-score < -1) on the cohort-level. Specific domains with severe impairment included executive function (color trails 2 assessment: -4.93, SD $\pm$ 3.20); verbal learning (AVLT-Total: -2.93, SD $\pm$ 1.66); verbal memory (AVLT-Recall: -3.21, SD $\pm$ 2.66); and speed of information processing (color trails 1 assessment: -2.20, SD $\pm$ 2.31) (Figure 2). While gross motor performance does not contribute to QNPZ-8, gross motor performance as assessed by timed gait was severely impaired, with a mean Z-score of -7.89 (SD $\pm$ 3.40).

Week 24 neurocognitive assessment

At week 24, three patients had at least moderate disability (median modified Rankin = 0, IQR 0-1), and 21% (6/28) of patients had a Karnofsky score <80 (Table 4).

At week 24, 61% (17/28) of patients had impaired cognitive function, and 25% (7/28) had severe impairment (Figure 3). Mean QNPZ-8 at 24 weeks was -1.62 (SD $\pm$ 1.29). Amongst the 28 patients tested at both time points, QNPZ-8 improved from a mean of -2.39 (SD $\pm$ 1.52) to -1.62 (SD $\pm$ 1.29). The most improved domains over these 16 weeks were fine motor (grooved pegboard, Z-score difference = 1.15) which improved to the mean of the HIV-negative Ugandan control group, and executive function (color trails 2 assessment, Z-score difference 1.32) which remained severely impaired (Figure 2). Other domains which remained impaired were processing speed (color trails 1: -1.32 (SD $\pm$ 1.66)) (symbol digit modality: -1.33 (SD $\pm$ 1.21)), verbal learning (AVLT-total: -1.86 (SD $\pm$ 1.65)), verbal memory (AVLT Recall: -2.16 (SD $\pm$ 2.01)), and motor speed (finger tapping: -1.58 (SD $\pm$ 1.20)). Color trails 1 and symbol digit modality also assess concentration and attention; however, these domains were judged unimpaired based on relatively normal results on tests of concentration and attention which do not test processing speed: digit span forward and backward (-0.76 SD $\pm$ 2.1; -0.14 SD $\pm$ 2.6 respectively). Timed gait remained severely impaired: mean Z-score was -5.11 (SD $\pm$ 3.69).

Of note, seven patients at eight weeks, and two patients at 24 weeks were too ill to complete any test and therefore all scores including QNPZ-8 are imputed 2 standard deviations

Figure 2. Impairment in neurocognitive domains at eight and 24 weeks in survivors of TBM. Mean cohort Z-scores in each neurocognitive assessment and the summary score (QNPZ-8) at both time points show improvement in most domains. A Z-score <-1 signifies impairment, and a Z-score <-2 signifies severe impairment. Error bars represent standard error. DSF: Digit Span Forward, DSB: Digit Span Backward, AVLTR: WHO-UCLA Audio Verbal Learning Test Recall, SDM: Symbol Digit Modality, GPB: grooved pegboard, QNPZ-8: Quantitative neurologic performance on eight modalities.

Figure 3. Proportions of the cohort that are no longer impaired in each assessment at week 24. Bars approaching 1 signify few participants with impairment in that domain. Majorities of the cohort have impairment in AVLTR, AVLTR, SDM, Finger tapping, Color Trails 1, Color Trails 2, Timed Gait, and the summary score (QNPZ-8). Impairment on any given assessment is defined as a Z-score <-1 . DSF: Digit Span Forward, DSB: Digit Span Backward, AVLTR: WHO-UCLA Audio Verbal Learning Test Total, AVLTR: WHO-UCLA Audio Verbal Learning Test Recall, SDM: Symbol Digit Modality, GPB: grooved pegboard, QNPZ-8: Quantitative neurologic performance on 8 modalities.

below the cohort mean. In a parallel analysis excluding these patients (Table 5), mean scores were slightly improved but relative differences between domains were similar in both populations (Timed Gait, Color trails 1, color trails 2, AVLT, AVLTR were most impaired; Digit span forward, digit span backward, verbal fluency, grooved pegboard were least impaired).

Depression screening

Moderate and severe depression, as defined by a PHQ-9 score ≥ 10 was present in a majority of the cohort (23/27 (85%) able to complete the questionnaire) at week 8. At week 24, rates of moderate and severe depression were somewhat lower (75%; 18/24), but still constituted a large majority of the cohort. Even with a higher cutoff (≥ 15), the majority screened positive for depression at both time points (Table 4). Among the 21 who completed the questionnaire at both time points, moderate and severe depression was present in 17 (81%) at week 8, and 15 (71%) at week 24.

Discussion

In this prospective study of 36 survivors of TBM in Uganda, we have reaffirmed the high degree of early functional disability present, demonstrated neurocognitive and functional improvement between two and six months, and described a phenotype of neurocognitive impairment predominantly in executive functioning, information processing speed, and verbal learning and memory. This phenotype is less apparent at eight weeks, when patients are often still recovering from their acute illness and are broadly impaired, but by 24 weeks becomes clear as some neurocognitive domains approach control group norms while others remained impaired. Notably, at this time many patients were judged as clinically well and

without significant disability (based on the modified Rankin Scale) by the study doctor, but there remained significant neurocognitive deficits that were identified on comprehensive neurocognitive testing. Longer follow-up is necessary to determine the durability of this impairment, and whether longer-term recovery is likely.

Many of the deficits identified were motor-related, including gross motor (timed gait), fine motor (grooved pegboard), and motor speed (finger tapping). Of the more explicitly cognitive domains, verbal learning and memory, processing speed, and executive function were especially affected. The deficits described mirror many of those found in a prior Taiwanese study (which did not test motor domains), where TBM survivors had significant deficits in processing speed (digit symbol), verbal comprehension (similarities), working memory (letter-number sequencing), and additionally, perceptual organization (block design, matrix reasoning)⁶. While this suggests potential generalizability of TBM neurocognitive outcomes between HIV-positive and HIV-negative populations, further study is necessary.

Reflecting the epidemiology of TBM in Uganda⁴², a majority of the cohort was HIV-positive and among those, a majority had a baseline CD4 T cell count < 200 cells/ μ L, putting them at significant risk of HIV-associated dementia⁴³. Dissecting the neurocognitive impacts of HIV infection and TBM is inherently difficult, and current definitions of HIV-associated dementia exclude patients with central nervous system opportunistic infections like TBM⁴⁴. The typical profile of neurocognitive impairment in HIV-associated dementia includes deficits in verbal learning and memory, executive functioning, attention,

Table 5. Mean Z-score with standard deviation on each neurocognitive test at week 8 and 24 in the full study cohort and in only participants who attempted neurocognitive assessment.

Neurocognitive Test	All Participants Week 8 (n=36)	Participants Who Attempted Week 8 (n=29)	All Participants Week 24 (n=28)	Participants Who Attempted Week 24 (n=26)
Digit Span Forward	-1.43 $\pm$ 2.24	-0.95 $\pm$ 2.24	-0.76 $\pm$ 2.11	-0.56 $\pm$ 2.09
Digit Span Backward	-1.01 $\pm$ 2.33	-0.40 $\pm$ 2.18	-0.14 $\pm$ 2.57	0.13 $\pm$ 2.51
AVLT	-2.93 $\pm$ 1.66	-2.41 $\pm$ 1.35	-1.86 $\pm$ 1.65	-1.63 $\pm$ 1.46
AVLT Recall	-3.21 $\pm$ 2.66	-2.56 $\pm$ 1.94	-2.16 $\pm$ 2.00	-1.83 $\pm$ 1.42
Symbol Digit Modality	-1.92 $\pm$ 1.23	-1.86 $\pm$ 1.36	-1.33 $\pm$ 1.21	-1.27 $\pm$ 1.26
Grooved pegboard	-1.53 $\pm$ 2.09	-1.22 $\pm$ 2.23	-0.20 $\pm$ 1.49	0.00 $\pm$ 1.58
Finger Tapping	-2.03 $\pm$ 1.16	-1.73 $\pm$ 1.09	-1.58 $\pm$ 1.20	-1.45 $\pm$ 1.17
Verbal Fluency	-1.37 $\pm$ 0.99	-1.09 $\pm$ 0.88	-0.90 $\pm$ 0.93	-0.77 $\pm$ 0.85
Color Trails 1	-2.20 $\pm$ 2.31	-2.24 $\pm$ 2.57	-1.32 $\pm$ 1.66	-1.27 $\pm$ 1.74
Color Trails 2	-4.93 $\pm$ 3.20	-4.99 $\pm$ 3.54	-3.65 $\pm$ 3.35	-3.58 $\pm$ 3.53
Timed Gait	-7.89 $\pm$ 3.41	-7.38 $\pm$ 3.61	-5.11 $\pm$ 3.69	-4.73 $\pm$ 3.63
QNPZ-8	-2.51 $\pm$ 1.43	-2.26 $\pm$ 1.49	-1.62 $\pm$ 1.29	-1.47 $\pm$ 1.24

Abbreviations: AVLT: WHO-UCLA Auditory Verbal Learning test (See Table 1)

and processing speed^{32,45}. The deficits we described in TBM survivors in memory, executive functioning, and processing speed overlap this profile, although the additional deficits in gross motor domains, and relatively good performance in tests of attention not relying on speed, are notable. When the same battery of neurocognitive tests was administered to an HIV-positive cohort in Uganda³², participants were impaired in verbal learning, gross motor, and executive function, but to a lesser degree than in this TBM cohort at 24 weeks (comparable Z-scores presented¹⁷). This suggests neurocognitive impairment after TBM beyond what would be expected from HIV alone. ART improves symptoms of HIV-associated dementia³⁰, and 24 week testing on TBM survivors in our study (16 weeks after ART initiation) showed significant but far from complete improvement from baseline. Longer follow-up and evidence of immune recovery is necessary to better understand the contribution of HIV to the neurocognitive impairment after TBM.

We found a high prevalence of depression in survivors of TBM at both eight and 24 weeks. This is consistent with findings of high rates of depression in South African children with TBM¹⁹. Interestingly, the rates of depression in this study are higher than in adult survivors of cryptococcal meningitis in Uganda (73% at one month in a 2010–2013 cohort, 62% in a 2015–2017 cohort)^{17,46}. While there has been little study of the relationship between TBM and depression, the pathophysiology and treatment of TBM in our cohort involves HIV infection, inflammation, neurologic injury, and glucocorticoids, all of which are also associated with depression^{47–51}. IL-6, known to play an important role in depression^{52–54}, including inhibiting the serotonin pathway, is significantly associated with the severity of TBM⁵⁵. Cognitive impairment is a known symptom of depression⁵⁶, so some of the cognitive impairment seen in the cohort could be attributable to depression. As prior psychiatric illness was not assessed, we cannot determine whether premorbid depression may have also contributed to risk of advanced HIV and TBM. Given the association between depression and HIV-induced immunosuppression¹⁴, it is notable that unlike the significant improvement in depression reported after ART initiation in survivors of cryptococcal meningitis^{17,57}, high rates of depression persisted in our cohort at six months, well after ART was initiated. Immunologic differences in the response to cryptococcal meningitis and TBM⁵⁵, known to be important in the development and persistence of depression^{58,59}, may partly explain this disparity. Differences between TBM and cryptococcal meningitis disease severity could further explain the difference in depressive symptoms, with TBM having higher rates of altered mental status while hospitalized^{46,60–62}, strokes^{7,8,63}, and persistent neurologic deficits. A comprehensive treatment of depression is essential to improve outcomes in TBM, and should be incorporated into follow-up and rehabilitation protocols.

The improvement in both motor and cognitive domains over six months is remarkable even without formal rehabilitation, but further recovery potential remains unknown. Given the predominance of motor impairment, physiotherapy could

provide significant benefits, and deserves further study. More specialized rehabilitation practices might show benefit in the recovery from deficits in processing speed, executive function, and memory. Rehabilitation protocols designed for stroke survivors, which are the most available worldwide^{22,24}, could be effective for TBM given that there is also a high prevalence of motor deficits, depression, and cognitive deficits (especially executive function and processing speed), although the exact phenotype of cognitive deficits differs depending on stroke location^{64,65}. This population (median age 35 years) are in the most economically active period of life and thus rehabilitation may prove to be cost-effective. Further investment in local physiotherapy is essential in sub-Saharan Africa, but increasing experience with telemedicine provides an alternate method of care delivery^{23,24}. Novel approaches, including brain-training video games, might be applicable for recovery from TBM as they have shown promise in improving working memory and processing speed in other populations^{66,67}.

Strengths of this study include standardization of results to a locally representative cohort and detailed neurocognitive profiling at two time-points. Specifically, the neurocognitive instrument used has been validated in both languages of administration, although a limitation is that little detail is available on the specifics of the translation process between English and Luganda and whether it met established guidelines. Other limitations include the small cohort size and lack of follow up beyond 6 months. The study was not powered to assess the impact of the trial treatment on neurocognitive outcomes, which may limit generalization to populations not receiving these non-standard TB therapies. However, the parent trial found no difference in mortality, functional status, or time to resolution of coma, although it too was not powered to assess these outcomes²⁵. There were also too few HIV-negative participants to assess for differences in neurocognitive outcomes between HIV-positive and negative participants. The control group had only 100 participants, limiting the ability to assume true population norms. The control group was more educated, but analysis of education-adjusted scores intended to minimize any impact. Larger studies will be necessary to investigate baseline risk factors for poor neurocognitive outcome. The same assessment was given to participants at 8 and 24 weeks in order to track neurocognitive improvement; however, this could incur an element of practice effects that explains some of the improvement in scores. We intended to mediate these effects with a 16 week gap between successive testing sessions, but since the control group did not take the assessment multiple times, it is possible we did not completely adjust for these effects.

Eight weeks from diagnosis may be too early to meaningfully determine neurocognitive outcomes in TBM survivors as a substantial proportion of participants (19%) at that time were remained too acutely ill to attempt any neurocognitive testing. While those participants were included in order to fairly represent the degree of impairment still present at 8 weeks and allow for comparison to the literature, their blanket impairment may not represent the phenotype of impairment in survivors who are further along in their recovery. Notably, by

12 weeks, only 7% of participants were too ill to participate, so the phenotype at this time point may be more representative.

Comprehensive neurocognitive testing of TBM survivors in sub-Saharan Africa is feasible. There is significant neurocognitive recovery between 2 and 6 months, but significant deficits remain in motor domains, as well as processing speed, verbal learning, and executive function. These findings highlight the need for neurorehabilitation and management of depression in TBM survivors.

Data availability

Underlying data

Repository name: Data Compass, <https://doi.org/10.17037/DATA.0000237268>

This project contains the following underlying data:

- Individual baseline results
- Individual clinical statuses at weeks 8 and 24
- Modified Rankin, Karnofsky performance, and PHQ-9 scores

- Individual raw scores for each test in the battery of neurocognitive tests
- Individual Z-scores on the neurocognitive tests

Data are available under the terms of the Data Sharing Agreement. Due to ethical considerations surrounding the sensitivity of the data in a vulnerable population, study consents limited the access to underlying data from this study. However, controlled access to the data posted in the above repository is permitted after signing of the agreement and IRB approval. Readers interested in the data can learn more by completing the application form on the [Data Compass repository](#), or by contacting the LSHTM Research Data Management Service at researchdatamanagement@lshtm.ac.uk with the dataset DOI.

Acknowledgements

We thank Dr. Ned Sacktor for his pioneering work in neurocognitive assessments in Africa.

References

1. Stadelman AM, Ellis J, Samuels THA, et al.: **Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis.** *Open Forum Infect Dis.* 2020; **7**(8): ofaa257. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Wang MG, Luo L, Zhang Y, et al.: **Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis.** *BMC Pulm Med.* 2019; **19**(1): 200. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Kent SJ, Crowe SM, Yung A, et al.: **Tuberculous meningitis: a 30-year review.** *Clin Infect Dis.* 1993; **17**(6): 987–994. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Verdon R, Chevret S, Laissy JP, et al.: **Tuberculous meningitis in adults: review of 48 cases.** *Clin Infect Dis.* 1996; **22**(6): 982–988. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Chan KH, Cheung RT, Fong CY, et al.: **Clinical relevance of hydrocephalus as a presenting feature of tuberculous meningitis.** *QJM.* 2003; **96**(9): 643–648. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Chen HL, Lu CH, Chang CD, et al.: **Structural deficits and cognitive impairment in tuberculous meningitis.** *BMC Infect Dis.* 2015; **15**: 279. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Dastur DK, Lalitha VS, Udani PM, et al.: **The brain and meninges in tuberculous meningitis-gross pathology in 100 cases and pathogenesis.** *Neurol India.* 1970; **18**(2): 86–100. [PubMed Abstract](#)
8. Thomas MD, Chopra JS, Walia BN: **Tuberculous meningitis (T.B.M.)(a clinical study of 232 cases).** *J Assoc Physicians India.* 1977; **25**(9): 633–639. [PubMed Abstract](#)
9. Thwaites GE, Nguyen DB, Nguyen HD, et al.: **Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.** *N Engl J Med.* 2004; **351**(17): 1741–1751. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Davis AG, Nightingale S, Springer PE, et al.: **Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis [version 1; peer review: 2 approved].** *Wellcome Open Res.* 2019; **4**: 178. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Kalita J, Misra UK, Ranjan P: **Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis.** *Eur J Neurol.* 2007; **14**(1): 33–37. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Ranjan P, Kalita J, Misra UK: **Serial study of clinical and CT changes in tuberculous meningitis.** *Neuroradiology.* 2003; **45**(5): 277–282. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Hestad KA, Chinyama J, Anitha MJ, et al.: **Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis.** *J Acquir Immune Defic Syndr.* 2019; **80**(1): 110–117. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Nakasujja N, Skolasky RL, Musisi S, et al.: **Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda.** *BMC Psychiatry.* 2010; **10**: 44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Cresswell FV, Bangdiwala AS, Meya DB, et al.: **Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes.** *Int J Infect Dis.* 2018; **68**: 77–78. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Milanini B, Paul R, Bahemana E, et al.: **Limitations of the International HIV Dementia Scale in the current era.** *AIDS.* 2018; **32**(17): 2477–2483. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Carlson RD, Rolfes MA, Birkenkamp KE, et al.: **Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.** *Metab Brain Dis.* 2014; **29**(2): 269–279. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Montgomery MP, Nakasujja N, Morawski BM, et al.: **Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.** *BMC Neurol.* 2017; **17**(1): 110. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Wait JW, Schoeman JF: **Behaviour profiles after tuberculous meningitis.** *J Trop Pediatr.* 2010; **56**(3): 166–171. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Gimigliano F, Negrini S: **The World Health Organization “Rehabilitation 2030: a call for action”.** *Eur J Phys Rehabil Med.* 2017; **53**(2): 155–168. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Zziwa S, Babikako H, Kwesiga D, et al.: **Prevalence and factors associated with utilization of rehabilitation services among people with physical disabilities in Kampala, Uganda. A descriptive cross sectional study.** *BMC Public Health.* 2019; **19**(1): 1742. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Khan F, Amaty B, Galea MP, et al.: **Neurorehabilitation: applied neuroplasticity.** *J Neurol.* 2017; **264**(3): 603–615. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Khanna M, Gowda GS, Bagevadi VI, et al.: **Feasibility and Utility of Tele-Neurorehabilitation Service in India: Experience from a Quaternary Center.** *J Neurosci Rural Pract.* 2018; **9**(4): 541–544. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

24. Sarfo FS, Adamu S, Awuah D, *et al.*: **Potential role of tele-rehabilitation to address barriers to implementation of physical therapy among West African stroke survivors: A cross-sectional survey.** *J Neurol Sci.* 2017; **381**: 203–208.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Cresswell FV, Meya DB, Kagimu E, *et al.*: **High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.** *Clin Infect Dis.* 2021; **73**(5): 876–884.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Cresswell FV, Tugume L, Bahr NC, *et al.*: **Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study.** *Lancet Infect Dis.* 2020; **20**(3): 308–317.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Cresswell FV, Ssebambulidde K, Grint D, *et al.*: **High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the Riff study) [version 1; peer review: 2 approved].** *Wellcome Open Res.* 2018; **3**: 83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Cholera R, Gaynes BN, Pence BW, *et al.*: **Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa.** *J Affect Disord.* 2014; **167**: 160–166.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Gelaye B, Williams MA, Lemma S, *et al.*: **Validity of the Patient Health Questionnaire-9 for depression screening and diagnosis in East Africa.** *Psychiatry Res.* 2013; **210**(2): 653–661.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Sacktor N, Nakasujja N, Skolasky R, *et al.*: **Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.** *Neurology.* 2006; **67**(2): 311–314.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Wong MH, Robertson K, Nakasujja N, *et al.*: **Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa.** *Neurology.* 2007; **68**(5): 350–355.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Robertson KR, Nakasujja N, Wong M, *et al.*: **Pattern of neuropsychological performance among HIV positive patients in Uganda.** *BMC Neurol.* 2007; **7**: 8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Maj M, D'Elia L, Satz P, *et al.*: **Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study.** *Arch Clin Neuropsychol.* 1993; **8**(2): 123–135.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Wechsler D: **Wechsler Adult Intelligence Scale-Revised.** The Psychological Corporation; 1981.
35. Spreen O, Strauss E: **A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 2nd Ed.** Oxford University Press; 1998; xvi: 736.
[Reference Source](#)
36. Robertson KR, Parsons TD, Sidtis JJ, *et al.*: **Timed Gait test: normative data for the assessment of the AIDS dementia complex.** *J Clin Exp Neuropsychol.* 2006; **28**(7): 1053–1064.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Klove H: **Clinical Neuropsychology.** *Med Clin North Am.* 1963; **47**: 1647–58.
[PubMed Abstract](#)
38. Reitan R: **Manual for Administration of Neuropsychological Test Batteries for Adults and Children.** Indiana University Press; 1969.
39. Smith A: **Symbol Digit Modalities Test: Manual.** Western Psychological Services; 1982.
40. D'Elia L, Satz P, Uchiyama C, *et al.*: **Color Trails Test: Professional Manual.** Psychological Assessment Resources; 1996.
41. Sacktor NC, Wong M, Nakasujja N, *et al.*: **The International HIV Dementia Scale: a new rapid screening test for HIV dementia.** *AIDS.* 2005; **19**(13): 1367–1374.
[PubMed Abstract](#)
42. Ellis J, Bangdiwala AS, Cresswell FV, *et al.*: **The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015–2017.** *Open Forum Infect Dis.* 2019; **6**(10): ofz419.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Bhaskaran K, Mussini C, Antinori A, *et al.*: **Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.** *Ann Neurol.* 2008; **63**(2): 213–221.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Antinori A, Arendt G, Becker JT, *et al.*: **Updated research nosology for HIV-associated neurocognitive disorders.** *Neurology.* 2007; **69**(18): 1789–1799.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Gallego L, Barreiro P, López-Ibor JJ: **Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection.** *AIDS Rev.* 2011; **13**(3): 171–179.
[PubMed Abstract](#)
46. Rhein J, Huppler Hullsiek K, Tugume L, *et al.*: **Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.** *Lancet Infect Dis.* 2019; **19**(8): 843–851.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Bell LCK, Noursadeghi M: **Pathogenesis of HIV-1 and *Mycobacterium tuberculosis* co-infection.** *Nat Rev Microbiol.* 2018; **16**(2): 80–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Benatti C, Blom JM, Rigillo G, *et al.*: **Disease-Induced Neuroinflammation and Depression.** *CNS Neural Disord Drug Targets.* 2016; **15**(4): 414–433.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Brown ES, Chandler PA: **Mood and Cognitive Changes During Systemic Corticosteroid Therapy.** *Prim Care Companion J Clin Psychiatry.* 2001; **3**(1): 17–21.
[PubMed Abstract](#) | [Free Full Text](#)
50. Orlovskaya S, Pedersen MS, Benros ME, *et al.*: **Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury.** *Am J Psychiatry.* 2014; **171**(4): 463–469.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Strawbridge R, Arnone D, Danese A, *et al.*: **Inflammation and clinical response to treatment in depression: A meta-analysis.** *Eur Neuropsychopharmacol.* 2015; **25**(10): 1532–1543.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Ting EY, Yang AC, Tsai SJ: **Role of Interleukin-6 in Depressive Disorder.** *Int J Mol Sci.* 2020; **21**(6): E2194.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Saylor D, Kumar A, Nakigozi G, *et al.*: **Interleukin-6 is associated with mortality and neuropsychiatric outcomes in antiretroviral-naïve adults in Rakai, Uganda.** *J Neurovirol.* 2019; **25**(6): 735–740.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Musunguzi K, Obuku A, Nakasujja N, *et al.*: **Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda.** *BMC Immunol.* 2018; **19**(1): 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Davis AG, Rohlwind UK, Proust A, *et al.*: **The Pathogenesis of Tuberculous Meningitis.** *J Leukoc Biol.* 2019; **105**(2): 267–280.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Culpepper L, Lam RW, McIntyre RS: **Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management.** *J Clin Psychiatry.* 2017; **78**(9): 1383–1394.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Lofgren SM, Velamakanni SS, Huppler Hullsiek K, *et al.*: **The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis [version 1; peer review: 1 approved with reservations].** *Wellcome Open Res.* 2021; **6**: 45.
[Publisher Full Text](#)
58. Lee CH, Giuliani F: **The Role of Inflammation in Depression and Fatigue.** *Front Immunol.* 2019; **10**: 1696.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Beurel E, Toups M, Nemeroff CB: **The Bidirectional Relationship of Depression and Inflammation: Double Trouble.** *Neuron.* 2020; **107**(2): 234–256.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Soria J, Metcalf T, Mori N, *et al.*: **Mortality in hospitalized patients with tuberculous meningitis.** *BMC Infect Dis.* 2019; **19**(1): 9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Raberahona M, Rakotoarivelo RA, Razafinambinintsoa T, *et al.*: **Clinical Features and Outcome in Adult Cases of Tuberculous Meningitis in Tertiary Care Hospital in Antananarivo, Madagascar.** *Biomed Res Int.* 2017; **2017**: 9316589.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Lofgren S, Hullsiek KH, Morawski BM, *et al.*: **Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.** *J Infect Dis.* 2017; **215**(5): 693–697.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Mishra AK, Arvind VH, Muliylil D, *et al.*: **Cerebrovascular injury in cryptococcal meningitis.** *Int J Stroke.* 2018; **13**(1): 57–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Barker-Collo S, Starkey N, Lawes CM, *et al.*: **Neuropsychological profiles of 5-year ischemic stroke survivors by Oxfordshire stroke classification and hemisphere of lesion.** *Stroke.* 2012; **43**(1): 50–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. McHutchison CA, Cvoro V, Makin S, *et al.*: **Functional, cognitive and physical outcomes 3 years after minor lacunar or cortical ischaemic stroke.** *J Neurol Neurosurg Psychiatry.* 2019; **90**(4): 436–443.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Anguera JA, Boccanfuso J, Rintoul JL, *et al.*: **Video game training enhances cognitive control in older adults.** *Nature.* 2013; **501**(7465): 97–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Bove RM, Rush G, Zhao C, *et al.*: **A Videogame-Based Digital Therapeutic to Improve Processing Speed in People with Multiple Sclerosis: A Feasibility Study.** *Neurol Ther.* 2019; **8**(1): 135–145.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Cresswell F, Quinn C: **Neurocognitive outcomes of HIV-associated tuberculous meningitis dataset.** [Data Collection]. London School of Hygiene & Tropical Medicine, London, United Kingdom. 2021.
<http://www.doi.org/10.17037/DATA.00002372>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 28 July 2022

<https://doi.org/10.21956/wellcomeopenres.19643.r51357>

© 2022 Belaunzarán-Zamudio P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pablo F. Belaunzarán-Zamudio

Division of AIDS, National Institutes of Allergy and Infectious Diseases (Contractor), Mexico City, Mexico

This is an observational, cohort study nested within a phase II, open-label, clinical trial designed to test if high-dose rifampin administered intravenously or orally would improve blood and CSF rifampin exposure in people with tuberculosis meningitis (TBM) in a population consisting predominantly of people living with HIV (PLHIV) receiving care in Uganda. In this manuscript, Carson Quinn and colleagues report the results of longitudinal neurocognitive assessments performed in 36 participants of said trial that survived the initial event of TBM and had at least 8 weeks of follow-up. Only a fraction of these (n=28) completed the neurocognitive evaluations 24 weeks after enrollment.

This is a small, but relevant study providing evidence that people surviving TBM may have significant cognitive impairments 8 and 24 weeks after having initiated treatment for tuberculosis and around 4 months after ART initiation. While the participants improved over time in general, the phenotypes of impairment were remarkably different at each timepoint: from a non-specific phenotype with moderate to severe impairments in several areas (including executive function, verbal learning, verbal memory; and speed of information processing) at week 8, to a severe impairment of predominantly fine motor and executive functions at week 24. Remarkably, the authors also observed high prevalence of depression in this population, that did not seem to decrease significantly over time, which contrasted with significant improvements in disability.

The article is well written, easy to follow, and the authors have provided, in my view, a coherent narrative of an important health problem with potential public health ramifications, on which not sufficient attention has been laid. The strength of the findings of the study is limited by the small sample size, relatively high attrition and short follow-up, and difficulties in measuring neurocognitive function, which the authors tried to address as best as possible and discussed in detail. Previous reviewers have pointed out several shortcomings, to which the authors responded adequately.

I just want to add that non-acknowledged limitation of this study, is that this is a secondary analysis of a randomized clinical trial, with strict inclusion and exclusion criteria, that may have undiscussed implications for external validity, even locally. This is not a population study with a sample size or study population designed to answer the specific question that this analysis is trying to answer. Previous studies have shown important differences in sociodemographic characteristics and clinical outcomes between participants in clinical trials and people receiving care through routine clinical care. This does not undermine the relevance of this study, but needs to be acknowledged as a limitation.

Also, while I agree with their conclusion that their findings highlight the need for neurorehabilitation and management of depression in TBM survivors; I would only add that larger studies with longer-term follow-up are needed to better characterize neurocognitive function outcomes in people recovering of tuberculous meningitis.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology of HIV care, therapeutic clinical trials

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 04 March 2022

<https://doi.org/10.21956/wellcomeopenres.19643.r48992>

© 2022 Saylor D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Deanna Saylor ¹ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA² University Teaching Hospital, Lusaka, Zambia³ MMED Neurology Program, School of Medicine, University of Zambia, Lusaka, Zambia

Dr. Quinn and team have adequately addressed all of my previous concerns, and I believe the revised manuscript has improved in clarity and in a more streamlined message. I believe it represents a very important contribution to the TBM literature and congratulate the authors on this important work.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.**Reviewer Expertise:** Neurocognitive impairment in HIV, neuro-infectious diseases, neuroepidemiology and clinical neurology in sub-Saharan Africa**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Version 1

Reviewer Report 11 November 2021

<https://doi.org/10.21956/wellcomeopenres.18727.r46454>

© 2021 Robbins R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reuben Robbins

¹ HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York City, NY, USA

² Columbia University, New York City, NY, USA

³ HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York City, NY, USA

⁴ Columbia University, New York City, NY, USA

This is a well-written manuscript describing neurocognitive outcomes among a small sample of Ugandan adults with tuberculosis meningitis (TBM), most of whom were also HIV-infected. The study describes neurocognitive functioning at 8 and 24 weeks post enrollment in a prospective cohort, phase 2 label randomized trial for TBM. The authors found high rates of global and domain specific impairment at 8 weeks and slightly less rates of impairment at 24 weeks. This study makes an important contribution to our understanding of neurocognitive functioning in HIV-associated TBM.

There are four concerns:

1. The title refers to HIV-associated TBM, yet two participants in the study do not have HIV. Why include them? Do they differ in any way from the HIV+ participants, whether demographically or neurocognitively?
2. The authors use the phrase "population mean" and "population norms" to describe the control sample's performance on the neuropsychological test battery. This is misleading, as a sample of 100 is not usually referred to as a population norm. Population based norms typically have sample sizes in the (many) thousands. These are control-based or convenience sample-based norms. They may or may not reflect the true Ugandan population performance on these tests.
3. Since the sample of TBM patients receive the same battery of tests twice, could some of the improvements be explained by practice effects? Did the control sample, from which norms were derived, complete the battery of neuropsychological tests more than once? And if so, do the norms take practice effects into account. If not, this is a limitation and must be noted as such.
4. There is little detail as to how the neuropsychological tests were adapted for Uganda. One of the source articles (citation #40) says, "All the tests had their instructions and content translated into Luganda." There is a growing body of literature describing some challenges of simple forward translations of neuropsychological tests. Without extensive cultural adaption that includes assessment of test acceptability and understandability that follow guidelines set forth by the International Test Commission and American Educational Research Association, it is not clear how "valid" the tests are for Uganda. That being said, because the battery has been used extensively there, the lack of information and procedures regarding adaptation can be noted as a limitation, and thus the tests may not accurately measure the cognitive domains they purport to and could bias performance downwards.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neuropsychology, HIV, test development and adaptation, international research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 25 Feb 2022

Carson Quinn

Dear Dr. Robbins,

We appreciate your thoughtful review and the recommendations you have made for improving the manuscript. We will respond to each of your comments below. A new revised version taking into account yours and Dr Saylor's comments has been submitted and should be available for review shortly.

1. *The title refers to HIV-associated TBM, yet two participants in the study do not have HIV. Why include them? Do they differ in any way from the HIV+ participants, whether demographically or neurocognitively?*

- You bring up a very important point about our study population, and a manner in which the manuscript suffered from imprecise wording. In designing the study, we endeavored to enroll a population that was representative of the TB Meningitis burden in Uganda. Past studies of neurocognitive outcomes of TBM have enrolled patients from southern and southeast Asia, and we wanted to ensure patients in Sub-Saharan Africa were represented in this literature. This Ugandan TBM population is largely, but not entirely, an HIV-positive population. However, as you state, our title and other high-level descriptions of the study refer to the cohort as "HIV-positive" which is misleading. We have

therefore changed our language to reflect that this is a "primarily HIV-positive cohort" and our goal was more so to reflect the population of TBM survivors in Uganda. Because there were only 2 HIV-negative participants it is challenging to definitively comment on group differences in outcomes or demographics. They were demographically similar to the cohort besides one being in the youngest quartile of age, and in outcomes they differed more from one another than from the cohort as a whole with one participant doing relatively well and the other poorly.

2. *The authors use the phrase "population mean" and "population norms" to describe the control sample's performance on the neuropsychological test battery. This is misleading, as a sample of 100 is not usually referred to as a population norm. Population based norms typically have sample sizes in the (many) thousands. These are control-based or convenience sample-based norms. They may or may not reflect the true Ugandan population performance on these tests.*
 - Thank you for pointing out this imprecise language on our part. We have adjusted the wording to refer to the "control group mean" rather than population mean and added the limited size of our control group as a limitation.
3. *Since the sample of TBM patients receive the same battery of tests twice, could some of the improvements be explained by practice effects? Did the control sample, from which norms were derived, complete the battery of neuropsychological tests more than once? And if so, do the norms take practice effects into account. If not, this is a limitation and must be noted as such.*
 - This is another excellent point. Practice effects certainly could have played a role, as the control sample to which we have normed the results did not have participants take the battery more than once. However, we hoped to lessen these effects by designing the study with a relatively long time between test administrations (4 months). However, as it could have still played a role, we have added this as a limitation to the study.
4. *There is little detail as to how the neuropsychological tests were adapted for Luganda. One of the source articles (citation #40) says, "All the tests had their instructions and content translated into Luganda." There is a growing body of literature describing some challenges of simple forward translations of neuropsychological tests. Without extensive cultural adaption that includes assessment of test acceptability and understandability that follow guidelines set forth by the International Test Commission and American Educational Research Association, it is not clear how "valid" the tests are for Uganda. That being said, because the battery has been used extensively there, the lack of information and procedures regarding adaptation can be noted as a limitation, and thus the tests may not accurately measure the cognitive domains they purport to and could bias performance downwards.*
 - Thank you for bringing up this important point that is essential to consider when undertaking neurocognitive testing on non-English speaking participants from cultural contexts unlike those of the participants the test was initially designed for. We were unable to obtain information on exactly how the tests were adapted for Luganda initially by our collaborators. However, this battery of tests, and the International HIV Dementia Scale one which they are based, have been validated in past studies with Luganda-speaking Ugandan

participants. Other studies have also assessed differences in test results between English and Luganda-speaking participants and found them to be minimal. For these reasons, this battery is commonly used in Uganda, and we are reassured that language differences are unlikely to be significantly biasing our results. This is now better-explained in the manuscript with appropriate citations, and added as a limitation.

Addendum to Response to Reviewer 1

After further consideration of the matter of treatment arm differences in outcomes, we have determined that inclusion of further data on neurocognitive outcomes between the different treatment arms would be counterproductive, as the intention of the study was to describe neurocognitive outcomes in TB meningitis not to test the impact of the trial treatment. With the low numbers in each group, no meaningful conclusions could be expected to be drawn. Differences in functional status and other clinical outcomes between the trial arms are included in the manuscript for the parent trial. This is now expounded upon further in the manuscript text, and noted as a limitation inherent in our small cohort.

Competing Interests: No competing interests were disclosed.

Reviewer Report 20 September 2021

<https://doi.org/10.21956/wellcomeopenres.18727.r45499>

© 2021 Saylor D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Deanna Saylor

¹ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

² University Teaching Hospital, Lusaka, Zambia

³ MMED Neurology Program, School of Medicine, University of Zambia, Lusaka, Zambia

⁴ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

⁵ University Teaching Hospital, Lusaka, Zambia

⁶ MMED Neurology Program, School of Medicine, University of Zambia, Lusaka, Zambia

Quinn, et al highlight the knowledge gap regarding neurocognitive and psychiatric outcomes in people with HIV (PWH) who survive TB meningitis (TBM) overall and in sub-Saharan Africa in particular and set out to determine these outcomes in a group of PWH TBM survivors in Uganda. They found nearly uniform neurocognitive impairment at 8 weeks, which improved but remained substantial at 24 weeks. In particular, verbal learning and memory, processing speed, and executive function were impaired as well as multiple domains of motor function. The authors also found high rates very high rates of depression at 8 weeks, and this did not change significantly at 24 weeks. Overall, this is an important study trying to address an important knowledge gap in the literature. However, there are important methodological and analytical decisions that were made

which need to be further explained and/or reconsidered in order to further strengthen the paper. Finally, I believe a more nuanced consideration of the limitations of the study is also needed. Specifically:

1. The authors state that the goal of the study was to understand post-TBM depression and cognitive outcomes in PWH living in sub-Saharan Africa. As such, it is surprising to me that the two HIV-uninfected participants were included in the study. These patients are likely to be quite different than those with HIV co-infection and increase the heterogeneity of the population and data obtained. Given that they represent such a small proportion of the study cohort, I would strongly consider excluding them from the analysis or, at minimum, provide a strong justification for why they should remain.
2. Please expand more on how the possibility that the treatment received in the trial may have contributed to neurocognitive and/or depression outcomes was assessed. It may also be prudent to list the possibility that this was not able to be completely accounted for in the analysis due to small sample sizes in each treatment group as a possible limitation.
3. Please provide greater detail about the demographics of HIV-uninfected controls used for neurocognitive norms. Was the language of administration similar? Were education levels distributed somewhat similarly? This is important in understanding the validity of the normative data used for the study cohort and may also be a limitation of the study.
4. Please justify the decision to include patients who were too sick to complete the analyses in the neurocognitive outcomes but not the depression outcomes. Do the authors really think including these patients is representative of the typical neurocognitive deficits after TBM? At a minimum, it would be great to present more detail about how results differed when excluding them.
5. It appears there is a significant number of participants with missing data on functional outcome measures at 8 weeks. Can this be explained?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurocognitive impairment in HIV, neuro-infectious diseases, neuroepidemiology and clinical neurology in sub-Saharan Africa

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 15 Oct 2021

Carson Quinn

Dear Dr. Saylor,

We appreciate your thoughtful review and the recommendations you have made for improving the manuscript. We will respond to each of your comments below:

- 1. The authors state that the goal of the study was to understand post-TBM depression and cognitive outcomes in PWH living in sub-Saharan Africa. As such, it is surprising to me that the two HIV-uninfected participants were included in the study. These patients are likely to be quite different than those with HIV co-infection and increase the heterogeneity of the population and data obtained. Given that they represent such a small proportion of the study cohort, I would strongly consider excluding them from the analysis or, at minimum, provide a strong justification for why they should remain.* You bring up a very important point about our study population, and a manner in which the manuscript suffered from imprecise wording. In designing the study, we endeavored to enroll a population that was representative of the TB Meningitis burden in Uganda. Past studies of neurocognitive outcomes of TBM have enrolled patients from southern and southeast Asia, and we wanted to ensure patients in Sub-Saharan Africa were represented in this literature. This Ugandan TBM population is largely, but not entirely, an HIV-positive population. However, as you state, our title and other high-level descriptions of the study refer to the cohort as "HIV-positive" which is misleading. We will therefore change our language to reflect that this is a "primarily HIV-positive cohort" and our goal was moreso to reflect the population of TBM survivors in Uganda.
- 2. Please expand more on how the possibility that the treatment received in the trial may have contributed to neurocognitive and/or depression outcomes was assessed. It may also be prudent to list the possibility that this was not able to be completely accounted for in the analysis due to small sample sizes in each treatment group as a possible limitation.* You are correct in wondering how the trial treatment could have impacted neurocognitive outcomes in survivors, and it is a question that we intend to study further in the future. This study was not powered to answer this question, and the numbers in each of the treatment groups that survived to neurocognitive assessment follow-up is too low to meaningfully comment on the differential impact of the trial treatments. However, in these small groups, there did not appear to be any significant difference in the summary neurocognitive score between the treatment groups. We will ensure that this data is provided in the revised manuscript (it is

currently present in the extended data that is available), and comment on this accordingly as a limitation of the manuscript.

3. *Please provide greater detail about the demographics of HIV-uninfected controls used for neurocognitive norms. Was the language of administration similar? Were education levels distributed somewhat similarly? This is important in understanding the validity of the normative data used for the study cohort and may also be a limitation of the study.* The HIV-negative control participants are cohorted by age and education in the same groups as our study population to allow for norming of the study data. The tests were also performed in Luganda and English according to participant preference for both the controls and study population. We will provide more complete demographics beyond this in the revised manuscript.
4. *Please justify the decision to include patients who were too sick to complete the analyses in the neurocognitive outcomes but not the depression outcomes. Do the authors really think including these patients is representative of the typical neurocognitive deficits after TBM? At a minimum, it would be great to present more detail about how results differed when excluding them.* The decision to include participants too sick to complete the neurocognitive assessment was one of the major challenges in designing this study; while both options (to include or not to include) had drawbacks, I will provide our rationale here and comment further in the revised manuscript. Our intended population was survivors of TB meningitis -- many of these survivors are unfortunately very functionally impaired and remain with a significant burden of chronic symptoms from their TBM. To exclude these patients would be to represent TBM as a less morbid disease than it in fact is. It is true that the imputed values for the neurocognitive assessments in these patients aren't particularly meaningful on an individual level, and do not further our goal of demonstrating a typical phenotype of impairment in TBM. However, they do serve to accurately represent the degree of neurocognitive impairment frequently present in survivors of TBM. We did perform a sensitivity analysis showing that inclusion of these patients did not importantly impact the neurocognitive domains affected. We will be sure to add this data to the revised manuscript and explain this limitation further. Furthermore, we hope for this study to contribute to a standardized format allowing cross-comparison for future studies of neurocognitive impairment in TBM, which may have goals of investigating risk factors for impairment -- in which case inclusion of these more impaired patients is essential.
5. *It appears there is a significant number of participants with missing data on functional outcome measures at 8 weeks. Can this be explained?* Thank you for noting this. This Karnofsky functional score were missing in patients deemed too impaired to complete neurocognitive assessment; however, as those scores are in fact available, they will be added to the revised manuscript.

Thank you again for your many constructive comments. We intend to submit a revised manuscript after receiving a second review so as to respond to comments from both reviewers. I am hopeful that the revised manuscript appropriately addresses your concerns.

Sincerely,

Carson Quinn on behalf of the authors

Competing Interests: None